Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€13.94

€13.94

1.860%
0.255
1.860%
€28.00
 
23.02.24 / Tradegate WKN: 566480 / Name: Evotec / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Evotec SE Stock

There is an upward development for Evotec SE compared to yesterday, with an increase of €0.26 (1.860%).
With 8 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 28 € there is potential for a 100.93% increase which would mean more than doubling the current price of 13.94 € for Evotec SE.
So far the community has only identified positive things for Evotec SE stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Evotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.

Pros and Cons of Evotec SE in the next few years

Pros
?
S********** s********
?
G***** c******* t* c**********
?
B****
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Evotec SE vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Evotec SE 1.860% 1.641% -7.562% -24.266% -34.761% -56.179% -32.124%
MorphoSys AG -0.240% 0.153% 100.306% 272.953% 91.672% -24.492% -28.412%
Novocure Ltd -0.500% -6.271% 7.745% -80.965% -1.576% -90.140% -
Ironwood Pharmaceuticals -2.840% -1.429% 10.400% 26.281% 32.692% 76.923% 7.813%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-08

Upon initial examination, the financial statements of Evotec, a prominent company within the Biotechnology and Medical Research industry, exhibit a combination of both favorable and concerning aspects. As a financial analyst, it is essential to delve into these documents to understand the company's financial health and potential opportunities for growth.

*Pros: *

Growing Total Assets: The total assets of Evotec have consistently grown over the last three years, increasing from €1,180,912,000 in 2019 to €1,462,895,000 in 2020, and further to €2,235,161,000 by the end of 2021. This growth reflects the company's ability to expand and generate value over time.

Comments

Buy Evotec AG
Show more

Buy Evotec AG
Show more

Sell Evotec AG
Show more

News

EQS-News: Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV
EQS-News: Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV
EQS-News: Evotec SE: Invitation to Conference Call: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE: Invitation to Conference Call
EQS-News: Evotec SE: Invitation to Conference Call
EQS-News: Evotec and Crohn´s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec and Crohn´s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies
EQS-News: Evotec and Crohn´s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies